Linda Fredrick
About
Linda Fredrick is a scholar working on Infectious Diseases, Hepatology and Epidemiology.
According to data from OpenAlex, Linda Fredrick has authored 28 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 14 papers in Hepatology and 13 papers in Epidemiology. Recurrent topics in Linda Fredrick's work include HIV/AIDS drug development and treatment (19 papers), Hepatitis C virus research (14 papers) and HIV Research and Treatment (9 papers). Linda Fredrick is often cited by papers focused on HIV/AIDS drug development and treatment (19 papers), Hepatitis C virus research (14 papers) and HIV Research and Treatment (9 papers). Linda Fredrick collaborates with scholars based in United States, Spain and France. Linda Fredrick's co-authors include Xavier Carbonell‐Estrany, Christian Rieger, Eric A. F. Simões, Jessie R. Groothuis, Ian Mitchell, Jan L. L. Kimpen, Joseph Gathe, Thomas Podsadecki, Ruth Soto-Malave and Min Tian and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Allergy and Clinical Immunology.
In The Last Decade
Linda Fredrick
28 papers receiving 758 citations
Peers
Linda Fredrick
Paul Collini United Kingdom
Bernardino Roca Spain
N. Mémain France
P. Puglièse France
Veronika Kohlbrenner United States
Gerrit Schreij Netherlands
N. Bernard France
Sebastian Noé Germany
Ana Rañó Spain
Pascale Longuet France
Citations per year, relative to Linda Fredrick Linda Fredrick (= 1×)
peers
Paul Collini
Countries citing papers authored by Linda Fredrick
Since
Specialization
Citations
This map shows the geographic impact of Linda Fredrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Fredrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Fredrick more than expected).
Fields of papers citing papers by Linda Fredrick
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Linda Fredrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Fredrick. The network helps show where Linda Fredrick may publish in the future.
Co-authorship network of co-authors of Linda Fredrick
This figure shows the co-authorship network connecting the top 25 collaborators of Linda Fredrick. A scholar is included among the top collaborators of Linda Fredrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Fredrick. Linda Fredrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pol, Stanislas, Alexander Thompson, Michelle A. Collins, et al.. (2024). Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study. Hepatology. 81(3). 1006–1018.
2.
Heo, Jeong, Yoon Jun Kim, Jin‐Woo Lee, et al.. (2021). Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. Gut and Liver. 15(6). 895–903.
3.
Zuckerman, Eli, Julio Gutiérrez, Douglas E. Dylla, et al.. (2020). Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 18(11). 2544–2553.e6.
4.
Cheinquer, Hugo, Lino Rodrigues, Mário Reis Álvares‐da‐Silva, et al.. (2020). Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil. Annals of Hepatology. 20. 100257–100257.
5.
Zuckerman, Eli, Julio Gutiérrez, Andrew Ustianowski, et al.. (2019). THU-198-Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies. Journal of Hepatology. 70(1). e251–e251.
6.
Wei, Lai, Jinlin Hou, Yan Luo, et al.. (2017). Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results. Journal of Hepatology. 66(1). S532–S532.
7.
Rockstroh, Jürgen K., Chloe Orkin, Rolando M. Viani, et al.. (2017). Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infectious Diseases. 4(3). ofx154–ofx154.
8.
Eron, Joseph J., Jay Lalezari, Jihad Slim, et al.. (2014). Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens. Journal of the International AIDS Society. 17(4S3). 19500–19500.
9.
Hermes, Ashwaq, K. Squires, Linda Fredrick, et al.. (2012). Meta-Analysis of the Safety, Tolerability, and Efficacy of Lopinavir/Ritonavir-Containing Antiretroviral Therapy in HIV-1–Infected Women. HIV Clinical Trials. 13(6). 308–323.
10.
Reynes, Jacques, Roger Trinh, Federico Pulido, et al.. (2012). Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study. AIDS Research and Human Retroviruses. 29(2). 256–265.
11.
Silva, Bárbara da, Linda Fredrick, Meenal Patwardhan, et al.. (2012). Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir from clinical trial and pharmacovigilance databases. International Journal of Clinical Pharmacology and Therapeutics. 50(6). 391–401.
12.
Reynes, Jacques, Federico Pulido, Ruth Soto-Malave, et al.. (2011). Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results. HIV Clinical Trials. 12(5). 255–267.
13.
Simões, Eric A. F., Xavier Carbonell‐Estrany, Christian Rieger, et al.. (2010). The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. Journal of Allergy and Clinical Immunology. 126(2). 256–262.
14.
Zajdenverg, Roberto, Thomas Podsadecki, Sharlaa Badal‐Faesen, et al.. (2010). Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1–Infected Subjects at 48 Weeks. JAIDS Journal of Acquired Immune Deficiency Syndromes. 54(2). 143–151.
15.
González‐García, Juan, Dani Cohen, Margaret Johnson, et al.. (2010). Short Communication: Comparable Safety and Efficacy with Once-Daily Versus Twice-Daily Dosing of Lopinavir/Ritonavir Tablets with Emtricitabine + Tenofovir DF in Antiretroviral-Naïve, HIV Type 1-Infected Subjects: 96 Week Final Results of the Randomized Trial M05-730. AIDS Research and Human Retroviruses. 26(8). 841–845.
16.
Gathe, Joseph, Barbara A. da Silva, Daniel E. Cohen, et al.. (2009). A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks. JAIDS Journal of Acquired Immune Deficiency Syndromes. 50(5). 474–481.
17.
Fredrick, Linda, et al.. (2009). Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naïve Subjects Screening for Two Clinical Trials in North America and Western Europe. HIV Clinical Trials. 10(2). 94–103.
18.
Cohen, Dani, Juan González‐García, Margaret A. Johnson, et al.. (2009). Comparable Safety and Effi cacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730.
19.
Campbell, Andrew, et al.. (2008). RSV HOSPITALIZATION RATES IN PRETERM CHILDREN IN THE SEASON FOLLOWING PALIVIZUMAB PROPHYLAXIS COMPARED TO CHILDREN WITHOUT PALIVIZUMAB PROPHYLAXIS. 93.
20.
Simões, Eric A. F., Jessie R. Groothuis, Xavier Carbonell‐Estrany, et al.. (2007). Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing. The Journal of Pediatrics. 151(1). 34–42.e1.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paul Collini Breakdown of academic impact, for papers by Bernardino Roca Breakdown of academic impact, for papers by N. Mémain Breakdown of academic impact, for papers by P. Puglièse Breakdown of academic impact, for papers by Veronika Kohlbrenner Breakdown of academic impact, for papers by Gerrit Schreij Breakdown of academic impact, for papers by N. Bernard Breakdown of academic impact, for papers by Sebastian Noé Breakdown of academic impact, for papers by Ana Rañó Breakdown of academic impact, for papers by Pascale Longuet